AC
ARCT icon

Aristides Capital’s Arcturus Therapeutics ARCT Stock Holding History

Aristides Capital’s Portfolio ARCT Stock Details ARCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-26,283
Closed -$161K – 178
2025
Q4 		$161K Buy
+26,283
New +$284K 0.03% 230

Other funds holding ARCT

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Aristides Capital's ARCT Position: Q1 2026 in Review

Aristides Capital sold out of Arcturus Therapeutics (ARCT) in Q1 2026, closing a stake of 26,283 shares — an estimated $161K sold.

Aristides Capital first reported a position in ARCT in Q4 2025 and held it in 1 quarter. The position peaked at $161K in Q4 2025. 124 funds tracked by Wall St. Rank hold ARCT as of Q1 2026.

  • Aristides Capital reported no remaining Arcturus Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Aristides Capital sold 26,283 Arcturus Therapeutics shares in Q1 2026, an estimated $161K.
  • Aristides Capital first reported a position in Arcturus Therapeutics in Q4 2025 and held it in 1 quarter.
  • Aristides Capital's Arcturus Therapeutics position peaked at $161K in Q4 2025.
  • 124 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q1 2026.

Based on Aristides Capital's 13F filing for Q1 2026, filed 14 May 2026.